Rifai is focused on enhancing the overall lifestyle of its clients. The fun and creative packaging reinforces the idea that ...

Dr. Moses Haregewoyn leads Automated Health Systems, which uses technology and structured management to expand access to public healthcare for individuals, providers, and agencies. The company has ...

Basis EHR established its first MVP release which subsequently made the system a preference among clinicians thus surpassing ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) ...

Rien ne garantit que les discussions avec Future Pak ou toute autre partie intéressée se traduiront par une opération. La Société tient à rassurer ses clients, ses employés et ses partenaires que, ...

Bernd Muehlenweg, Ph.D., Senior Vice President, Head of Global Business Development, Cell Therapy, Evotec; Non-Executive Director, Sernova Vlad Seitan, Ph.D., Chief ...

CEDAR PARK, Texas, April 15, 2025 (GLOBE NEWSWIRE) -- Ascension Seton is deepening its commitment to patient-centered care in Central Texas by acquiring full ownership of Cedar Park Medical Center.

“The initiation of the Phase 1 clinical trial being conducted by our development partner CSPC Pharmaceutical Group in China is a significant milestone for Radiance and RB-164™ (SYS6005),” said Robert ...

There is no assurance that discussions with Future Pak or any other interested party will result in a transaction. The Company would like to reassure its clients, employees and partners that while ...

Raw Garden is doubling down on its California roots and community connections with a massive 4/20 activation across the state. Here’s a look at what’s happening: A limited-time promotional offer on ...

The options have an exercise price of $2.79 per share, which is equal to the closing price of Cardiff Oncology's common stock on April 14, 2025. Each option will vest over a 4-year period, with 25% of ...

IPAX-Linz is a single-arm Phase 2 investigator-initiated trial (IIT). IPAX-Linz evaluates the safety, tolerability and preliminary efficacy of TLX101 therapy, in combination with external beam ...